The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $180.51

Today's change+2.81 +1.58%
Updated November 26 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $180.51

Today's change+2.81 +1.58%
Updated November 26 4:00 PM -5GMT. Delayed by at least 15 minutes.

Spdr S&P Biotech Etf Hits New 52-week High

Spdr S&P Biotech Etf closed up sharply Wednesday, rallying (U.S.)$2.81 or 1.58% to (U.S.)$180.51 and setting a new 52-week high. Over the last five days, shares have gained 6.21% and 38.64% year to date. Shares have outperformed the S&P 500 by 25.73% during the last year.

Key company metrics

  • Open(U.S.) $177.74
  • Previous close(U.S.) $177.70
  • High(U.S.) $180.65
  • Low(U.S.) $177.45
  • Bid / Ask-- / --
  • YTD % change+38.64%
  • Volume216,541
  • Average volume (10-day)273,658
  • Average volume (1-month)372,911
  • Average volume (3-month)411,214
  • 52-week range(U.S.) $115.31 to (U.S.) $180.65
  • Beta1.13
  • Trailing P/E4.53×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $1.55
  • Dividend yield0.86%
  • Trailing EPS(U.S.) $39.84
Updated November 26 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+6,254.35%

The data is not available to provide analysis on this topic.
Company Books

S&P TSX1.10%Sector:FinancialsIndustry:Investment Trusts
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2014Q4/2013Q2/2013Q4/2012
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201312/31/2013Jun 30, 201306/30/2013Dec 31, 201212/31/2012Jun 30, 201206/30/2012
Revenue3231
Total other revenue--------
Total revenue3231
Gross profit--------
Total cost of revenue--------
Total operating expense2111
Selling / general / administrative2111
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income1110
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax200125-11147
Income after tax200125-11147
Income tax, total0000
Net income200125-11147
Total adjustments to net income--------
Net income before extra. items200125-11147
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items200125-11147
Inc. avail. to common incl. extra. items200125-11147
Diluted net income200125-11147
Dilution adjustment----0--
Diluted weighted average shares8978
Diluted EPS excluding extraordinary itemsvalue per share26.0113.83-1.5018.31
Dividends per sharevalue per share0.130.090.200.00
Diluted normalized EPSvalue per share26.0113.83-1.5018.31